iov-3001
·Code: IOV-3001
iov-3001: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2, Open-label Study of a Modified Interleukin-2 Fusion Protein (IOV-3001) in Participants With Previously Treated, Unresectable or Metastatic Melanoma Who Will Receive Lifileucel
Frequently asked questions
Who is developing iov-3001?
iov-3001 is being developed by IOVANCE BIOTHERAPEUTICS, INC..
How many clinical trials involve iov-3001?
BioSniper tracks 1 clinical trial involving iov-3001.
Get deeper analysis on iov-3001
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis